Therapeutic Peptides Across the Cancer-Immunity Cycle: Advances and Challenges
Comprehensive review of how therapeutic peptides can enhance cancer immunotherapy by targeting each step of the cancer-immunity cycle, from antigen presentation to checkpoint signaling.
Quick Facts
What This Study Found
Therapeutic peptides can enhance cancer immunotherapy by targeting multiple steps of the cancer-immunity cycle, though stability and conformation challenges limit their current clinical efficacy.
Key Numbers
Review covers peptide applications across all stages of the cancer-immunity cycle, from antigen presentation to tumor killing.
How They Did This
Comprehensive narrative review of recent advancements in therapeutic peptides targeting the cancer-immunity cycle, including clinical progress and emerging strategies.
Why This Research Matters
Many cancer patients do not respond to current immunotherapies. Peptides that can boost multiple steps of anti-cancer immunity could help more patients benefit from immunotherapy while potentially reducing side effects compared to full-size antibody drugs.
The Bigger Picture
As cancer immunotherapy becomes standard of care, the need for more precise tools to boost immune responses grows. Peptides occupy a sweet spot between small molecules and antibodies — large enough for specificity but small enough for tissue penetration. This review maps the landscape of how peptides can be deployed across the entire cancer-immunity cycle.
What This Study Doesn't Tell Us
Narrative review that may not comprehensively cover all published evidence. Many discussed peptides are in early clinical stages. Stability and delivery challenges acknowledged but not fully resolved.
Questions This Raises
- ?Which step of the cancer-immunity cycle is most amenable to peptide-based intervention?
- ?Can peptide stability issues be solved through stapling, cyclization, or formulation approaches?
- ?Will peptide-based immunotherapies complement or compete with antibody checkpoint inhibitors?
Trust & Context
- Key Stat:
- Full CIC coverage Therapeutic peptides can target every step of the cancer-immunity cycle: antigen presentation, immune regulation, and checkpoint signaling
- Evidence Grade:
- Moderate evidence: comprehensive review of a rapidly evolving field, though individual peptide approaches are at varying stages of clinical validation.
- Study Age:
- Published in 2024. Captures the latest advances in peptide-based cancer immunotherapy.
- Original Title:
- Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.
- Published In:
- Acta pharmaceutica Sinica. B, 14(9), 3818-3833 (2024)
- Authors:
- Zhang, Xiaokun(2), Wu, Ye, Lin, Jiayi(2), Lu, Shengxin, Lu, Xinchen, Cheng, Aoyu, Chen, Hongzhuan, Zhang, Weidong, Luan, Xin
- Database ID:
- RPEP-09656
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How can peptides help fight cancer?
Peptides can boost the immune system's ability to find and kill cancer cells by targeting multiple steps: presenting tumor markers to immune cells, activating immune responses, and blocking checkpoint signals that tumors use to hide from immunity.
Are peptide cancer therapies available now?
Some peptide-based cancer treatments are in clinical trials, but most are still in development. Current immunotherapies use larger antibody drugs, but peptides could offer similar benefits with better tissue penetration and fewer side effects in the future.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09656APA
Zhang, Xiaokun; Wu, Ye; Lin, Jiayi; Lu, Shengxin; Lu, Xinchen; Cheng, Aoyu; Chen, Hongzhuan; Zhang, Weidong; Luan, Xin. (2024). Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.. Acta pharmaceutica Sinica. B, 14(9), 3818-3833. https://doi.org/10.1016/j.apsb.2024.05.013
MLA
Zhang, Xiaokun, et al. "Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.." Acta pharmaceutica Sinica. B, 2024. https://doi.org/10.1016/j.apsb.2024.05.013
RethinkPeptides
RethinkPeptides Research Database. "Insights into therapeutic peptides in the cancer-immunity cy..." RPEP-09656. Retrieved from https://rethinkpeptides.com/research/zhang-2024-insights-into-therapeutic-peptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.